Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.64 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8882817 | 0.90 | AKR1B1 (0.56) | SRD5A2SRD5A1KDM4EALDH1A1GAA | |
| SCHEMBL10447995 | 0.88 | SRD5A2 (0.55) | SRD5A2SRD5A1KDM4EALDH1A1GAA | |
| SCHEMBL26637991 | 0.86 | TBXAS1 (0.58) | SRD5A2SRD5A1TBXAS1TBXA2R | |
| SCHEMBL17336259 | 0.84 | SRD5A2 (0.55) | SRD5A2SRD5A1ALDH1A1ROCK2 | |
| SCHEMBL751196 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1GAAHPGDMAPK1 | |
| SCHEMBL205466 | 0.82 | SRD5A2 (0.63) | SRD5A2SRD5A1ALDH1A1MAPK1ROCK2 | |
| SCHEMBL10922029 | 0.81 | TTR (0.55) | SRD5A2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL30625936 | 0.80 | MAPT (0.56) | SRD5A2SRD5A1KDM4EALDH1A1GAA | |
| SCHEMBL1407977 | 0.80 | MAPT (0.56) | SRD5A2SRD5A1KDM4EALDH1A1GAA | |
| SCHEMBL15301425 | 0.80 | SRD5A2 (0.45) | SRD5A2SRD5A1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | SRD5A2 307/4885SRD5A1 197/4885KDM4E 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.